Inovio Halts Head And Neck Cancer Trials On Safety Concerns
This article was originally published in The Gray Sheet
Executive Summary
Inovio Biomedical prematurely halted a pivotal study investigating its tumor ablation technology in head and neck cancer June 5 after an independent data monitoring committee raised concerns about adverse events